VIP Peptides Ā· Research Compound
Semax Research Profile
Semax is a synthetic 7-amino-acid peptide derived from the ACTH(4ā10)
fragment. It is presented here for laboratory research only.
Peptide length
Source fragment
Vial quantity
Use classification
Product Information
About Semax
Semax has the sequence
Met-Glu-His-Phe-Pro-Gly-Pro and is derived from the
ACTH(4ā10) fragment of adrenocorticotropic hormone.
The supplied document describes its design as intended to retain
neurotrophic research effects while eliminating adrenal-stimulating
activity. This design description does not establish clinical
effectiveness.
Product form: lyophilized powder. Confirm product quantity and form
against the vial label.
Product Specifications
| Product | Semax |
|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro |
| Peptide length | 7 amino acids |
| Derived from | ACTH(4ā10) fragment |
| Vial quantity | 10 mg |
| Format | Lyophilized powder |
| Purity / identity | See matching batch report, if available |
Research Areas
What Research Has Examined
Neurotrophic Signaling
The supplied document describes research involving BDNF, its
receptor TrkB, NGF and GAP-43. These findings relate to research
on neuronal survival and synaptic processes; they do not confirm
clinical benefits.
Preclinical Injury Models
Animal studies have examined Semax in models of ischemia and spinal
cord injury. Results from animal models do not establish human
safety or effectiveness.
Inflammatory Pathways
The document describes experimental findings involving changes in
pro-inflammatory gene activity and neurotrophic pathways in
ischemia models.
Early In-vitro Research
Early laboratory research has explored copper-chelating activity
and amyloid-beta aggregation. These findings have not been shown
to produce clinical outcomes.
Quality Documentation
Batch & Testing Information
The supplied document recommends HPLC purity testing and mass
spectrometry identity confirmation. It mentions HPLC ā„98% as a
verification benchmark, not as a confirmed result for this product.
The document does not include a batch-specific COA or measured
purity result. Add a COA link only when you have the report for the
exact batch. For injectable forms, the source document also recommends
independent sterility data; no sterility claim is made here.
Evidence & Safety
Limitations and Regulatory Status
The supplied document describes most human data as coming from Russian
clinical use and smaller studies; large Western randomized controlled
trials are lacking. Cognitive-enhancement effects in healthy adults
have not been confirmed in controlled Western trials. Long-term outcomes
and standardized human dosing remain incompletely established.
The document states that Semax is not FDA-approved for any indication
and is research-only in the United States. It describes human safety
information as limited.
Reported issues in the source document include nasal irritation and
occasional fatigue, sedation or mood changes. Long-term effects and
potential tolerance remain unknown. Animal findings do not establish
long-term safety in humans.
consumption, clinical use, diagnosis, treatment, cure, mitigation or
prevention of disease.

![Selank [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/selank-300x300.jpg)
![GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) [100mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/ghk-300x300.jpg)
![AOD-9604 (Anti-Obesity Drug 9604) [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/aod9604-300x300.jpg)
![SNAP-8 (Acetyl Octapeptide-3) [10mg]](https://vipresearchpeptides.com/wp-content/uploads/2026/10/snap8-300x300.jpg)
Reviews
There are no reviews yet.